Innoviva Inc (INVA) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally.
Total Assets Chart for Innoviva Inc
Innoviva Inc (INVA) total assets for FY2025 were USD 1.6B, a 25.7% change from FY2024. Innoviva Inc's total assets grew from USD 246.9M in 2000 to USD 1.6B in 2025 (562.4% over 25 years). Total assets compound annual growth rate: 5-year CAGR of 10.3%, 10-year CAGR of 14.4%, 20-year CAGR of 10.4%.
Total Assets (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $1.49B
- Implied Share Price
- $20.66
- Enterprise Value
- $1.21B
- Revenue (TTM)
- $440.00M
- EBITDA
- $195.39M
- Profit Margin
- 81.19%
- Trailing P/E
- 4.83
- Forward P/E
- 8.88
- Price/Book (MRQ)
- 1.23
- Price/Sales (TTM)
- 3.39
- EV/EBITDA
- 2.61
- EV/Revenue
- 2.75
- Dividend Yield
- —
- Book Value
- $16.98
- Free Cash Flow (FY2025)
- $186.43M
- Free Cash Flow Yield
- 12.49%
Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.